Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Mesenchymal stem cell secretome attenuates disease-associated microglial activation and cognitive decline in TBI-associated neuroinflammation.

Rasiah PK., Ismael S., Elshaer S., Awad AM., Salman M., Wang Z.

Animal Study on Neuroinflammation, published in Neurochem Int (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Neurochem Int (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42342036
DOI
10.1016/j.neuint.2026.106210

Abstract (original English)

Therapeutic options for traumatic brain injury (TBI) remain limited, in part due to injury-induced activation of microglia toward disease-associated microglia (DAM) phenotypes that contribute to persistent neuroinflammation and cognitive decline. We evaluated whether non-invasive intranasal delivery of mesenchymal stem cell secretome can enhance recovery after TBI by modulating microglial DAM signaling. Adult C57BL/6 mice underwent moderate controlled cortical impact (CCI) TBI. Adipose Stem Cell-derived Concentrated Conditioned Media (ASC-CCM) (∼20 ng protein/day, four doses) was administered intranasally, while sham and TBI controls received saline. Cognitive and memory functions assessed at 7 and 30 days post-injury showed TBI mice with impairments in learning, working, and long-term memory, while ASC-CCM-treated TBI mice performed similar to sham. These functional deficits correlated with increased astrogliosis (GFAP) and apoptosis (TUNEL), both of which were attenuated by ASC-CCM. TBI induced a time-dependent increase in astrocyte-associated APOE in the ipsilateral peri-lesion area and TYROBP in activated microglia near the impact site; ASC-CCM treatment significantly reduced both markers. Transcriptomic analysis of peri-lesion tissue at days 7 and 30 confirmed robust upregulation of DAM-associated genes (APOE, TYROBP, TREM2) after TBI, which was mitigated by intranasal ASC

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMicrogliaBrain Injuries, TraumaticMice, Inbred C57BLMiceMaleMesenchymal Stem CellsCognitive DysfunctionSecretomeNeuroinflammatory Diseases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research